Imbach_subbed.qxp 12/2/09 17:11 Page 92
Paediatric Haematology
Haematol, 2004;124(6):796–801. Med, 2006;355(16):1672–81. 58. Li Z, Nardi MA, Karpatkin S, Role of molecular mimicry to HIV-1
14. Sood R, Wong W, Jeng M, Zehnder JL, Gene expression profile 37. Jenkins JM, Williams D, Deng Y, et al., Phase 1 clinical study of peptides in HIV-1-related immunologic thrombocytopenia,
of idiopathic thrombocytopenic purpura (ITP), Pediatr Blood eltrombopag, an oral, nonpeptide thrombopoietin receptor Blood, 2005;106(2):572–6.
Cancer, 2006;47(Suppl. 5):675–7. agonist, Blood, 2007;109(11):4739–41. 59. Siragam V, Crow AR, Brinc D, et al., Intravenous
15. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV, 38. Cines DB, Pumping out platelets, Blood, immunoglobulin ameliorates ITP via activating Fc gamma
Demonstration of a thrombocytopenic factor in the blood of 2007;109(11):4591–92 receptors on dendritic cells, Nat Med, 2006;12(6):688–92.
patients with thrombocytopenic purpura, J Lab Clin Med, 39. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, 60. Siragam V, Brinc D, Crow AR, et al., Can antibodies with
1951;38(1):1–10. Kloczko J, Hassani H, Mayer B, et al., Eltrombopag for the specificity for soluble antigens mimic the therapeutic effects of
16. Schwartz RS, Immune thrombocytopenic purpura—from agony treatment of chronic idiopathic thrombocytopenic purpura, intravenous IgG in the treatment of autoimmune disease?,
to agonist, N Engl J Med, 2007;357(22):2299–2301. N Engl J Med, 2007;357(22):2237–47. J Clin Invest, 2005;115(1):155–60.
17. Imbach P, Barandun S, d’Apuzzo V, et al., High-dose 40. Panzer S, New therapeutic options for adult chronic immune 61. Crow AR, Song S, Siragam V, Lazarus AH, Mechanisms of
intravenous gammaglobulin for idiopathic thrombocytopenic thrombocytopenic purpura: a brief review, Vox Sang, action of intravenous immunoglobulin in the treatment of
purpura in childhood, Lancet, 1981;1(8232):1228–31. 2008;94(1):1–5. immune thrombocytopenia, Pediatr Blood Cancer, 2006;47
18. Imbach P, Wagner HP, Berchtold W, et al., Intravenous 41. Beck CE, Nathan PC, Parkin PC, et al., Corticosteroids versus (Suppl. 5):710–13.
immunoglobulin versus oral corticosteroids in acute immune intravenous immune globulin for the treatment of acute 62. Semple JW, Aslam R, Kim M, et al., Platelet-bound
thrombocytopenic purpura in childhood, Lancet, 1985;31; immune thrombocytopenic purpura in children: a systematic lipopolysaccharide enhances Fc receptor-mediated phagocytosis
2(8453):464–8. review and meta-analysis of randomized controlled trials, of IgG-opsonized platelets, Blood, 2007;109(11):4803–5.
19. Kuter DJ, New thrombopoietic growth factors, Blood, J Pediatr, 2005;147(4):521–7. 63. Semple JW, Bruce S, Freedman J, Suppressed natural killer cell
20071;109(11):4607–16. 42. Wang J, Wiley JM, Luddy R, et al., Chronic immune activity in patients with chronic autoimmune thrombocytopenic
20. McMillan R, Wang L, Tomer A, et al., Suppression of in vitro thrombocytopenic purpura in children: assessment of rituximab purpura, Am J Hematol, 1991;37(4):258–62.
megakaryocyte production by antiplatelet autoantibodies from treatment, J Pediatr, 2005;146(2):217–21. 64. Semple JW, Milev Y, Cosgrave D, et al., Differences in serum
adult patients with chronic ITP, Blood, 2004;103(4):1364–9. 43. Bennett CM, Rogers ZR, Kinnamon DD, et al., Prospective cytokine levels in acute and chronic autoimmune
21. Buchanan GR, Kühne T, Bolton-Maggs P, et al., Frequency, phase 1/2 study of rituximab in childhood and adolescent thrombocytopenic purpura: relationship to platelet phenotype
location and timing of severe hemorrhage in children with chronic immune thrombocytopenic purpura, Blood, 2006;1; and antiplatelet T-cell reactivity, Blood, 1996;87(10):4245–54.
newly-diagnosed idiopathic thrombocytopenic purpura: study of 107(7):2639–42. 65. Tha-In T, Metselaar HJ, Tilanus HW, et al., Intravenous
the Intercontinental Childhood ITP Study Group, Blood, 44. Parodi E, Nobili B, Perrotta S, et al., Rituximab (anti-CD20 immunoglobulins suppress T-cell priming by modulating the
2003;102:298a. monoclonal antibody) in children with chronic refractory bidirectional interaction between dendritic cells and natural
22. Bolton-Maggs PH, Moon I, Assessment of UK practice for symptomatic immune thrombocytopenic purpura: efficacy and killer cells, Blood, 2007;110(9):3253–62.
management of acute childhood idiopathic thrombocytopenic safety of treatment, Int J Hematol, 2006l;84(1):48–53. 66. Kappers-Klunne MC, van’t Veer MB, Cyclosporin A for the
purpura against published guidelines, Lancet, 1997;30; 45. Willis F, Marsh JC, Bevan DH, et al., The effect of treatment with treatment of patients with chronic idiopathic thrombocytopenic
350(9078):620–23. Campath-1H in patients with autoimmune cytopenias, Br J purpura refractory to corticosteroids or splenectomy, Br J
23. Buchanan GR, Adix L, Grading of hemorrhage in children with Haematol, 2001;114(4):891–8. Haematol, 2001;114(1):121–5.
idiopathic thrombocytopenic purpura, J Pediatr, 2002;141(5): 46. Kotb R, Pinganaud C, Trichet C, et al., Efficacy of 67. Emilia G, Morselli M, Luppi M, et al., Long-term salvage
683–8. mycophenolate mofetil in adult refractory auto-immune therapy with cyclosporin A in refractory idiopathic
24. Lilleyman JS, Intracranial haemorrhage in idiopathic cytopenias: a single center preliminary study, Eur J Haematol, thrombocytopenic purpura, Blood, 2002;99(4):1482–5.
thrombocytopenic purpura. Paediatric Haematology Forum of 2005;75(1):60–64. 68. Hrstková H, Bajer M, Michálek J, Recombinant human
the British Society for Haematology, Arch Dis Child, 47. Andersen JC, Response of resistant idiopathic thrombocytopenic interferon alpha-2a therapy in children with chronic immune
1994;71(3):251–3. purpura to pulsed high-dose dexamethasone therapy, N Engl J thrombocytopenic purpura, J Pediatr Hematol Oncol,
25. Imbach P, Kühne T, Müller D, et al., Childhood ITP: 12 months Med, 1994;330(22):1560–64. 2002;24(4):299–303.
follow-up data from the prospective registry I of the 48. Kühne T, Blanchette V, Buchanan GR, et al., Intercontinental 69. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al., Therapeutic
Intercontinental Childhood ITP Study Group (ICIS), Pediatr Blood Childhood ITP Study Group. Splenectomy in children with efficacy of intravenous immunoglobulin preparations depends
Cancer, 2006;46(3):351–6. idiopathic thrombocytopenic purpura: A prospective study of on the immunoglobulin G dimers: studies in experimental
26. Akatsuka J, Fujisawa K, Ishidoya N, et al., Long-term follow-up 134 children from the Intercontinental Childhood ITP Study immune thrombocytopenia, Blood, 2001;98(4):1095–9.
study of children with chronic ITP, Blut, 1989;59(1):105–8. Group, Pediatr Blood Cancer, 2007;49(6):829–34. 70. Bennett CM, Rogers ZR, Kinnamon DD, et al., Prospective
27. Tamary H, Kaplinsky C, Levy I, et al., Chronic childhood 49. Vesely S, Buchanan GR, Cohen A, et al., Self-reported phase 1/2 study of rituximab in childhood and adolescent
idiopathic thrombocytopenia purpura: long-term follow-up, Acta diagnostic and management strategies in childhood idiopathic chronic immune thrombocytopenic purpura, Blood, 2006;
Paediatr, 1994;83(9):931–4. thrombocytopenic purpura: results of a survey of practicing 107(7):2639–42.
28. Imbach P, Akatsuka J, Blanchette V, et al., pediatric hematology/oncology specialists, J Pediatr Hematol 71. Stasi R, Del Poeta G, Stipa E, et al., Response to B-cell
Immunthrombocytopenic purpura as a model for pathogenesis Oncol, 2000;22(1):55–61. depleting therapy with rituximab reverts the abnormalities of
and treatment of autoimmunity, Eur J Pediatr, 1995;154:60–64 50. Vesely SK, Buchanan GR, Adix L, et al., American Society of T-cell subsets in patients with idiopathic thrombocytopenic
29. Aronis S, Platokouki H, Mitsika A, et al., Seventeen years of Pediatric Hematology/Oncology, 2001. Self-reported initial purpura, Blood, 2007;110(8):2924–30.
experience with chronic idiopathic thrombocytopenic purpura in management of childhood idiopathic thrombocytopenic 72. Kjaersgaard M, Aslam R, Kim M, et al., Epitope specificity and
childhood. Is therapy always better?, Pediatr Hematol Oncol, purpura: results of a survey of members of the American Society isotype of monoclonal anti-D antibodies dictate their ability to
1994;11(5):487–98. of Pediatric Hematology/Oncology, 2001, J Pediatr Hematol inhibit phagocytosis of opsonized platelets, Blood, 2007;110(4):
30. Klaassen RJ, Blancette VS, Barnard D, et al., Validity, relaibility, Oncol, 2003;25(2):130–33. 1359–61.
and responsiveness of a new measure of health-related quality 51. George JN, Woolf SH, Raskob GE, et al., Idiopathic 73. Arnold DM, Dentali F, Crowther MA, et al., Systematic review:
of life in children with immune thrombocytopenic purpura: the thrombocytopenic purpura: a practice guideline developed by efficacy and safety of rituximab for adults with idiopathic
Kids’ ITP Tolls, J Pediatr, 2007;150:510–15. explicit methods for the American Society of Hematology, thrombocytopenic purpura, Ann Intern Med, 2007;146(1):
31. Cines DB, Blanchette VS, Immune thrombocytopenic purpura, Blood, 1996;88(1):3–40. 25–33.
N Engl J Med, 2002;346(13):995–1008. 52. British Committee for Standards in Haematology General 74. Samuelsson A, Towers TL, Ravetch JV, Anti-inflammatory
32. Blanchette V, Imbach P, Andrew M, et al., Randomised trial of Haematology Task Force. Guidelines for the investigation and activity of IVIG mediated through the inhibitory Fc receptor,
intravenous immunoglobulin G, intravenous anti-D, and oral management of idiopathic thrombocytopenic purpura in adults, Science, 2001;291(5503):484–6.
prednisone in childhood acute immune thrombocytopenic children and in pregnancy, Br J Haematol, 2003;120(4):574–96. 75. Ravetch JV, Bolland S, IgG Fc receptors, Annu Rev Immunol,
purpura, Lancet, 1994;344(8924):703–7. 53. Imbach P, Kühne T, Blanchette V, Intercontinental Childhood 2001;19:275–90.
33. Gaines AR, Disseminated intravascular coagulation associated ITP Study Group (ICIS). The State of the Art Expert Meeting of 76. Viard I, Wehrli P, Bullani R, et al., Inhibition of toxic epidermal
with acute hemoglobinemia or hemoglobinuria following the Intercontinental Childhood ITP Study Group (ICIS), J Pediatr necrolysis by blockade of CD95 with human intravenous
Rh(0)(D) immune globulin intravenous administration for Hematol Oncol, 2003;25(Suppl. 1):S1–84. immunoglobulin, Science, 1998;282(5388):490–93.
immune thrombocytopenic purpura, Blood, 2005;106(5): 54. Kühne T, Imbach P, Critical Issues and Future Research of ITP, 77. Salama A, Kiefel V, Mueller-Eckhardt C, Effect of IgG
1532–7. Pediatr Blood Cancer, 2006;47(Suppl. 5):649–745. anti-Rho(D) in adult patients with chronic autoimmune
34. Tarantino MD, Young G, Bertolone SJ, et al., Acute ITP Study 55. Kühne T, Blanchette V, Buchanan GR, et al., Intercontinental thrombocytopenia, Am J Hematol, 1986;22(3):241–50.
Group. Single dose of anti-D immune globulin at 75µg/kg is as Childhood ITP Study Group. Splenectomy in children with 78. Andrew M, Blanchette VS, Adams M, et al., A multicenter study
effective as intravenous immune globulin at rapidly raising the idiopathic thrombocytopenic purpura: A prospective study of of the treatment of childhood chronic idiopathic
platelet count in newly diagnosed immune thrombocytopenic 134 children from the Intercontinental Childhood ITP Study thrombocytopenic purpura with anti-D, J Pediatr, 1992;120:
purpura in children, J Pediatr, 2006;148(4):489–94. Group, Pediatr Blood Cancer, 2007;49(6):829–34. 522–7.
35. Newland A, Caulier MT, Kappers-Klunne M, et al., An 56. Chia WK, Blanchette V, Mody M, et al., Characterization of 79. Borgna-Pignatti C, Battisti L, Zecca M, Locatelli F, Treatment of
open-label, unit dose-finding study of AMG 531, a novel HIV-1-specific antibodies and HIV-1-crossreactive antibodies to chronic childhood immune thrombocytopenic purpura with
thrombopoiesis-stimulating peptibody, in patients with immune platelets in HIV-1-infected haemophiliac patients, Br J Haematol, intramuscular anti-D immunoglobulins, Br J Haematol,
thrombocytopenic purpura, Br J Haematol, 2006;135(4):547–53 1998;103(4):1014–22. 1994;88(3):618–20.
36. Bussel JB, Kuter DJ, George JN, et al., AMG 531, a 57. Blanchette V, Childhood chronic immune thrombocytopenic
thrombopoiesis-stimulating protein, for chronic ITP, N Engl J purpura (ITP), Blood Rev, 2002;16(1):23–6.
92 EUROPEAN HAEMATOLOGY
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100